Tafinlar
Tafinlar
$10,000.00
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type.
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type. BRAF is part of the mitogen-activated protein kinase (MAPK) signal transduction pathway, which is critical in tumor cell proliferation. The MAPK pathway controls cell proliferation following growth receptor stimulation. The typical binding of the ligand to the receptor triggers a chain of events that includes the activation of a series of downstream effectors, one of these being the RAF series of serine/threonine kinases, including BRAF.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Tafinlar : Non-small cell lung cancer (NSCLC)
16 Tafinlar : Melanoma
LIST OF FIGURES
8 Figure 1: Tafinlar for non-small cell lung cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary for Tafinlar in non-small cell lung cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment summary for Tafinlar in non-small cell lung cancer
12 Figure 4: Tafinlar sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
24 Figure 5: Tafinlar in melanoma – SWOT analysis
25 Figure 6: Datamonitor Healthcare’s drug assessment summary of Tafinlar for melanoma
26 Figure 7: Datamonitor Healthcare’s drug assessment summary of Tafinlar for melanoma
28 Figure 8: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Tafinlar drug profile
7 Table 2: Mekinist and Tafinlar pivotal trial data in non-small cell lung cancer
13 Table 3: Tafinlar sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
15 Table 4: Tafinlar patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
17 Table 5: Tafinlar drug profile
19 Table 6: Tafinlar pivotal trial data in melanoma
22 Table 7: Tafinlar ongoing late-phase clinical trials in melanoma
29 Table 8: Tafinlar sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
31 Table 9: Tafinlar patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
